



## Calcium-Permeable Ion Channels as Targets in Pharmacotherapy

Guest Editor:

### Dr. Hussein N. Rubaiy

Department of Laboratory  
Medicine, Division of Clinical  
Pharmacology, Karolinska  
Institute & Karolinska University  
Hospital, C1:68, 141 86  
Stockholm, Sweden

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

Ion channels are pore-forming proteins that are involved and play essential roles in very important physiological and pathological processes; hence, they serve as therapeutic drug targets.  $\text{Ca}^{2+}$  signaling governs both millisecond-scale cellular activities, such as muscular contraction, and slower functions lasting hours or days, such as cell migration and gene transcription.

$\text{Ca}^{2+}$ -permeable ion channels permit the influx or outflux of  $\text{Ca}^{2+}$  across the cell membrane and play a critical role in human physiology and pathology. This issue will focus on the  $\text{Ca}^{2+}$ -permeable ion channels that are responsible for the influx of extracellular  $\text{Ca}^{2+}$ , and these channels are the voltage-gated L- and T-type, TRP superfamily, ORAs (1-3), Piezo (1, 2), and P2X receptors, which are ligand-gated ion channels.

This Special Issue aims to provide a comprehensive summary of current knowledge of the structure, regulation, function and pharmacology of  $\text{Ca}^{2+}$ -permeable ion channels in human diseases and disorders as therapeutic targets.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)